| scholarly article | Q13442814 |
| P356 | DOI | 10.1016/J.TRIPLEO.2004.05.017 |
| P698 | PubMed publication ID | 15356467 |
| P2093 | author name string | Arlete Emily Cury | |
| Esther Goldenberg Birman | |||
| Cesar Augusto Migliorati | |||
| P2860 | cites work | In vitro and in vivo anticandidal activity of human immunodeficiency virus protease inhibitors | Q28368771 |
| Effectiveness of potent antiretroviral therapies on the incidence of opportunistic infections before and after AIDS diagnosis | Q33939861 | ||
| The role of yeasts other than Candida albicans in oropharyngeal candidiasis | Q34608320 | ||
| Elevated aspartic proteinase secretion and experimental pathogenicity of Candida albicans isolates from oral cavities of subjects infected with human immunodeficiency virus. | Q35467162 | ||
| Development of interpretive breakpoints for antifungal susceptibility testing: conceptual framework and analysis of in vitro-in vivo correlation data for fluconazole, itraconazole, and candida infections. Subcommittee on Antifungal Susceptibility Te | Q36855581 | ||
| Effects of the human immunodeficiency virus (HIV) proteinase inhibitors saquinavir and indinavir on in vitro activities of secreted aspartyl proteinases of Candida albicans isolates from HIV-infected patients. | Q39471544 | ||
| Treatment of oral candidiasis in HIV infection | Q40637659 | ||
| Multicenter Brazilian study of oral Candida species isolated from AIDS patients | Q43469225 | ||
| Oral candidiasis as a marker of acute retroviral illness | Q43529190 | ||
| Evidence that members of the secretory aspartyl proteinase gene family, in particular SAP2, are virulence factors for Candida vaginitis. | Q43621423 | ||
| The epidemiology of non-albicans Candida in oropharyngeal candidiasis in HIV patients | Q44024805 | ||
| Emergence of oropharyngeal candidiasis caused by non-albicans species of Candida in HIV-infected patients | Q45218609 | ||
| Changing prevalence of human immunodeficiency virus-associated oral lesions | Q45740232 | ||
| Changing prevalence of oral manifestations of human immuno-deficiency virus in the era of protease inhibitor therapy | Q45743952 | ||
| Human immunodeficiency virus type 1 protease inhibitor attenuates Candida albicans virulence properties in vitro | Q45748092 | ||
| Recovery of the immune system with antiretroviral therapy: the end of opportunism? | Q52038588 | ||
| A comparison of secretory proteinases from different strains of Candida albicans. | Q54513063 | ||
| Impact of protease inhibitor therapy on HIV-related oropharyngeal candidiasis | Q58000940 | ||
| Frequency of oropharyngeal candidiasis in HIV-infected patients on protease inhibitor therapy | Q58006233 | ||
| Oral Lesions in HIV/AIDS Patients Undergoing Highly Active Antiretroviral Treatment Including Protease Inhibitors: A New Face of Oral AIDS? | Q60222685 | ||
| HIV-Protease Inhibitors Reduce Cell Adherence of Candida Albicans Strains by Inhibition of Yeast Secreted Aspartic Proteases | Q61658939 | ||
| Oral findings in people with or at high risk for AIDS: a study of 375 homosexual males | Q68794160 | ||
| Effect of HAART on natural history of AIDS-related opportunistic disorders | Q74147323 | ||
| Decline in the rate of oral opportunistic infections following introduction of highly active antiretroviral therapy | Q74185951 | ||
| The effect of antiretroviral therapy on the prevalence of oral manifestations in HIV-infected patients: a UK study | Q77342530 | ||
| Role of protease inhibitors in preventing recurrent oral candidosis in patients with HIV infection: a prospective case-control study | Q77425301 | ||
| HIV protease inhibitors influence the prevalence of oral candidosis in HIV-infected patients: a 2-year study | Q77713221 | ||
| HIV-1 protease inhibitors | Q95819985 | ||
| P433 | issue | 3 | |
| P921 | main subject | candidiasis | Q273510 |
| P304 | page(s) | 301-310 | |
| P577 | publication date | 2004-09-01 | |
| P1433 | published in | Oral Surgery Oral Medicine Oral Pathology Oral Radiology and Endodontics | Q15763254 |
| P1476 | title | Oropharyngeal candidiasis in HIV-infected patients under treatment with protease inhibitors | |
| P478 | volume | 98 |
| Q34878614 | HIV aspartyl protease inhibitors as promising compounds against Candida albicans André Luis Souza dos Santos |
| Q34303424 | Oropharyngeal Candida colonization in human immunodeficiency virus infected patients |
| Q35254046 | Species distribution and susceptibility profile to fluconazole, voriconazole and MXP-4509 of 551 clinical yeast isolates from a Romanian multi-centre study |
| Q38953226 | The HIV aspartyl protease inhibitor ritonavir impairs planktonic growth, biofilm formation and proteolytic activity in Trichosporon spp. |
Search more.